RevCycleAI Brief
Published researchAI-native denial management and insurance revenue recovery platform that works claims end-to-end across payer portals, calls, corrected claims, medical records and appeals, with RCM specialists handling complex exceptions.
✦ Ask RevCycleAI about Amperos Health
Pro AI analystGo deeper on competitors, positioning, buyers, funding and market signals.
Unlock Ask RevCycleAI →Key findings
Research highlightsAmperos reports more than 3,000 clinical locations across all 50 states and nearly $700M of annual recovered revenue across more than 500,000 claims; diligence should validate the customer mix, denominator and durability of those outcomes.
The company reports 22% more recovered per claim at up to 50% lower cost than traditional vendors. Buyers should compare performance by payer, specialty, claim age and denial class rather than rely on blended recovery metrics.
The April 2026 Series A materially changes the company profile: Amperos is now a venture-backed scale-up pursuing broader end-to-end insurance recovery, not simply a denial follow-up automation tool.
Amperos raised a $16M Series A led by Bessemer Venture Partners, with participation from Uncork Capital and Neo.
Amperos published a Tend case study as it expanded customer proof around AI-driven insurance recovery.
RevCycleAI Intelligence Scores
MethodologyMarket Matrix: Major Contender · Impact 58 · Capability 71